Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifermin to Prevent Autoimmunity After Alemtuzumab in Multiple Sclerosis
NCT01712945Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jun 2012
- Primary completion
- Aug 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of palifermin in autoimmune disease, sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Jun 2012; status: terminated.
02
Drugs
palifermin
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT01712945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712945.